scholarly journals Establishment of Human Ultra-Low Passage Colorectal Cancer Cell Lines Using Spheroids from Fresh Surgical Specimens Suitable for In Vitro and In Vivo Studies

2012 ◽  
Vol 3 ◽  
pp. 196-206 ◽  
Author(s):  
Satyajit Ray ◽  
Russell C. Langan ◽  
John E. Mullinax ◽  
Tomotake Koizumi ◽  
Hong-Wu Xin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Colorectal Cancer Cell ◽  
In Vivo Studies ◽  
Colorectal Cancer Cell Lines ◽  
Low Passage

scholarly journals Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo

2012 ◽  
Vol 92 (11) ◽  
pp. 1607-1622 ◽  
Author(s):  
Susann Peickert ◽  
Julia Waurig ◽  
Claudia Dittfeld ◽  
Antje Dietrich ◽  
Yvette Garbe ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Colorectal Cancer Cell ◽  
Colorectal Cancer Cell Lines ◽  
Cd133 Protein

Precision cancer therapy through nanoparticle delivery of siRNA against KRAS.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 260-260
Author(s):  
Matthew S. Strand ◽  
Hua Pan ◽  
Julie G. Grossman ◽  
Peter S. Goedegebuure ◽  
Timothy Fleming ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Colorectal Cancers ◽  
Mouse Pancreas ◽  
Colorectal Cancer Cell Lines ◽  
Human And Mouse

260 Background: Small interfering RNA (siRNA) has potential for highly specific gene manipulation, making it attractive for delivering precision therapy to cancer patients. However, efforts to employ siRNA therapeutically have been limited by its short half-life in circulation, low target tissue specificity, and cellular entrapment within endosomes. We utilized serum-stable, cell-penetrating, and endosomolytic peptide-based nanoparticles (NPs) to overcome these obstacles and deliver siRNA against KRAS to KRAS-mutant human and mouse pancreas and colorectal cancers. Methods: Human and mouse pancreas and colorectal cancer cell lines were tested for NP uptake in vitro utilizing fluorescent siRNAs. Uptake was assessed via fluorescent microscopy and flow cytometry (FC). Mice bearing tumors from these cells were injected IV with the same NP, and uptake was assessed with an in vivo imaging system (IVIS), and FC. Cell lines were treated with KRAS-siRNA NP and KRAS knockdown was assessed by real-time PCR. Results: Mouse and human pancreas and colorectal cancer cell lines took up NP in vitro, with signal detected within > 93% of cells at 24 hours. Tumors from these cells grown in mice were strongly fluorescent after IV injection of fluorescent NP within 2 hours, and until at least 30 hours. FC of a tumor treated with fluorescent NP showed that 86% of tumor cells expressed fluorescent signal 24 hours post-injection. IVIS revealed signal in mouse liver and kidneys, but when assessed by FC, only 17.8% and 13.5% of cells from these tissues were fluorescent, respectively. The brain, heart, lungs, spleen, and pancreas of mice receiving injections were negative. Cancer cell lines exposed to KRAS-siRNA NP for 48 hours express KRAS at levels that are 4.5 to 15.1% of untreated cells. Conclusions: Human and mouse pancreas and colorectal cancers efficiently and specifically take up NP in vitro and in vivo. Selected limitations of siRNA are overcome with this NP delivery system, and NP-packaged siRNA effectively inhibits KRAS. This platform represents a highly specific approach to targeting tumor genes of interest, which may ultimately enable selective knockdown of putative drivers of tumor progression.

scholarly journals Characterization of novel low passage primary and metastatic colorectal cancer cell lines

Oncotarget ◽  
2016 ◽  
Vol 7 (12) ◽  
pp. 14499-14509 ◽  
Author(s):  
Arnoud Boot ◽  
Jaap van Eendenburg ◽  
Stijn Crobach ◽  
Dina Ruano ◽  
Frank Speetjens ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Cancer Cell Lines ◽  
Colorectal Cancer Cell ◽  
Colorectal Cancer Cell Lines ◽  
Low Passage

Morindone From Morinda Citrifolia as a Potential Antiproliferative Agent Against Colorectal Cancer Cell Lines

2021 ◽  
Author(s):  
Cheok Wui Chee ◽  
Nor hisam Zamakshshari ◽  
Vannajan Lee ◽  
Iskandar Abdullah ◽  
Rozana Othman ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
In Silico ◽  
Cancer Cell Lines ◽  
Morinda Citrifolia ◽  
Colorectal Cancer Cell ◽  
Root Bark ◽  
Colorectal Cancer Cell Lines

Abstract There is an increasing demand in developing new, effective, and affordable anti-cancer against colon and rectal. In this study, our aim is to identify the potential anthraquinone compounds from the root bark of Morinda citrifolia to be tested in vitro against colorectal cancer cell lines. Eight potential anthraquinone compounds were successfully isolated, purified and tested for both in-silico and in-vitro analyses. Based on the in-silico prediction, two anthraquinones, morindone and rubiadin, exhibit a comparable binding affinity towards multitargets of β-catenin, MDM2-p53 and KRAS. Subsequently, we constructed a 2D interaction analysis based on the above results and it suggests that the predicted anthraquinones from Morinda citrifolia offer an attractive starting point for potential antiproliferative agents against colorectal cancer. In vitro analyses further indicated that morindone and damnacanthal have significant cytotoxicity effect and selectivity activity against colorectal cancer cell lines.

Sign in / Sign up

Export Citation Format

Share Document